Publication

Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype

Hermans, B. C. M., Derks, J., Groen, H. J. M., Stigt, J. A., van Suylen, R. J., Hillen, L. M., van den Broek, E. C., Speel, E-J. M. & Dingemans, A-M. C., Dec-2019, In : Endocrine Connections. 8, 12, p. 1600-1606 7 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Hermans, B. C. M., Derks, J., Groen, H. J. M., Stigt, J. A., van Suylen, R. J., Hillen, L. M., van den Broek, E. C., Speel, E-J. M., & Dingemans, A-M. C. (2019). Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype. Endocrine Connections, 8(12), 1600-1606. https://doi.org/10.1530/EC-19-0372

Author

Hermans, Bregtje C M ; Derks, Jules ; Groen, Harry J M ; Stigt, Jos A ; van Suylen, Robert Jan ; Hillen, Lisa M ; van den Broek, Esther C ; Speel, Ernst-Jan M ; Dingemans, Anne-Marie C. / Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67 : a unique subtype. In: Endocrine Connections. 2019 ; Vol. 8, No. 12. pp. 1600-1606.

Harvard

Hermans, BCM, Derks, J, Groen, HJM, Stigt, JA, van Suylen, RJ, Hillen, LM, van den Broek, EC, Speel, E-JM & Dingemans, A-MC 2019, 'Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype', Endocrine Connections, vol. 8, no. 12, pp. 1600-1606. https://doi.org/10.1530/EC-19-0372

Standard

Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67 : a unique subtype. / Hermans, Bregtje C M; Derks, Jules; Groen, Harry J M; Stigt, Jos A; van Suylen, Robert Jan; Hillen, Lisa M; van den Broek, Esther C; Speel, Ernst-Jan M; Dingemans, Anne-Marie C.

In: Endocrine Connections, Vol. 8, No. 12, 12.2019, p. 1600-1606.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Hermans BCM, Derks J, Groen HJM, Stigt JA, van Suylen RJ, Hillen LM et al. Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype. Endocrine Connections. 2019 Dec;8(12):1600-1606. https://doi.org/10.1530/EC-19-0372


BibTeX

@article{b76d79980df64c61ac2fe89263f3bf02,
title = "Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67: a unique subtype",
abstract = "INTRODUCTION: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40-80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up.METHODS: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1).RESULTS: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5-18.5 months). Mean Ki-67 PI was 59% (range 15-100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11-23 months) vs. 5 months (95% CI 0.7-9 months), p=0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified and both SCLC-like (n=6) and NSCLC-like (n=2) subtype were present. No MEN1 mutation was found.CONCLUSION: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype.",
author = "Hermans, {Bregtje C M} and Jules Derks and Groen, {Harry J M} and Stigt, {Jos A} and {van Suylen}, {Robert Jan} and Hillen, {Lisa M} and {van den Broek}, {Esther C} and Speel, {Ernst-Jan M} and Dingemans, {Anne-Marie C}",
year = "2019",
month = dec,
doi = "10.1530/EC-19-0372",
language = "English",
volume = "8",
pages = "1600--1606",
journal = "Endocrine Connections",
issn = "2049-3614",
publisher = "BIOSCIENTIFICA LTD",
number = "12",

}

RIS

TY - JOUR

T1 - Large cell neuroendocrine carcinoma with a solitary brain metastasis and low Ki-67

T2 - a unique subtype

AU - Hermans, Bregtje C M

AU - Derks, Jules

AU - Groen, Harry J M

AU - Stigt, Jos A

AU - van Suylen, Robert Jan

AU - Hillen, Lisa M

AU - van den Broek, Esther C

AU - Speel, Ernst-Jan M

AU - Dingemans, Anne-Marie C

PY - 2019/12

Y1 - 2019/12

N2 - INTRODUCTION: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40-80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up.METHODS: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1).RESULTS: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5-18.5 months). Mean Ki-67 PI was 59% (range 15-100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11-23 months) vs. 5 months (95% CI 0.7-9 months), p=0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified and both SCLC-like (n=6) and NSCLC-like (n=2) subtype were present. No MEN1 mutation was found.CONCLUSION: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype.

AB - INTRODUCTION: Stage IV large cell neuroendocrine carcinoma (LCNEC) of the lung generally presents as disseminated and aggressive disease with a Ki-67 proliferation index (PI) 40-80%. LCNEC can be subdivided in two main subtypes: the first harboring TP53/RB1 mutations (small cell lung carcinoma (SCLC)-like), the second with mutations in TP53 and STK11/KEAP1 (non-small cell lung carcinoma (NSCLC)-like). Here we evaluated 11 LCNEC patients with only a solitary brain metastasis and evaluate phenotype, genotype and follow-up.METHODS: Eleven LCNEC patients with solitary brain metastases were analyzed. Clinical characteristics and survival data were retrieved from medical records. Pathological analysis included histomorphological analysis, immunohistochemistry (pRB and Ki-67 PI) and next generation sequencing (TP53, RB1, STK11, KEAP1 and MEN1).RESULTS: All patients had N0 or N1 disease. Median overall survival (OS) was 12 months (95% confidence interval (CI) 5.5-18.5 months). Mean Ki-67 PI was 59% (range 15-100%). In 6/11 LCNEC Ki-67 PI was ≤40%. OS was longer for Ki-67 ≤40% compared to >40% (17 months (95% CI 11-23 months) vs. 5 months (95% CI 0.7-9 months), p=0.007). Two patients were still alive at follow-up after 86 and 103 months, both had Ki-67 ≤40%. 8/11 patients could be subclassified and both SCLC-like (n=6) and NSCLC-like (n=2) subtype were present. No MEN1 mutation was found.CONCLUSION: Stage IV LCNEC with a solitary brain metastasis and N0/N1 disease show in the majority of cases Ki-67 PI ≤40% and prolonged survival, distinguishing them from general LCNEC. This unique subgroup can be both of the SCLC-like and NSCLC-like subtype.

U2 - 10.1530/EC-19-0372

DO - 10.1530/EC-19-0372

M3 - Article

C2 - 31751303

VL - 8

SP - 1600

EP - 1606

JO - Endocrine Connections

JF - Endocrine Connections

SN - 2049-3614

IS - 12

ER -

ID: 110836460